Insight Brief
April 18, 2017

Clinical Trials Laboratories in the Immuno-Oncology Setting

Increased demands lead to increased opportunities
Over the past decade there has been a large paradigm shift in the immuno-oncology (I/O) landscape with more than 45 immuno-oncology drugs approved in the United States and hundreds of immuno-oncology studies registered or ongoing. Immuno-oncology is one of the most important developments to arise within oncology drug development. It has the potential to improve the lives of countless patients facing cancer today and in the near future.

The development of immuno-oncology products offers a new era of treatment options for physicians and patients. However, the level of sophistication required for biomarker selection, trial design, technology implementation, testing and commercialization planning is unprecedented. With this shift to I/O products, drug developers and clinical trial laboratories are adjusting their approaches to better match the new requirements for success. Learn more about how clinical trial laboratories are utilizing multiple technologies and innovative new solutions to support this new era of immuno-oncology clinical development.

Radha Krishnan, MD, Chief Pathologist and Senior Medical Director

Related Services:
Central Laboratory Considerations for Deploying a Global Companion Diagnostics Solution

World CDx Europe 2018

Genomic Based Solutions for Your Immuno-oncology Drug Development Needs

Genomics-based biomarker approach

New Opportunities for Immuno-oncology Clinical Development Programs through T cell/B cell Repertoire Profiling

Immune repertoire profiling provides better outcomes for immuno-oncology development programs

The Power of the Central Laboratory for Immuno-Oncology Drug Development

Validating Flow Cytometry Assays for Immuno-Oncology Trials in the Central Lab

Molecular Medicine Tri-Conference 2017

Read More